Avalere Predicts Genomic Medicine Interventions will be Subject of CMS National Coverage Decisions
January 25, 2012
Avalere Predicts Genomic Medicine Interventions will be Subject of CMS National Coverage Decisions
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- With MDx Usage and Costs on the Rise, UnitedHealthCare Urges Reimbursement Reform
March 14, 2012 / Pharmacogenomics Reporter - With Top-line Deep-C Trial Data, Exact Sciences Gears Up for FDA and CMS Submissions for Cologuard
April 24, 2013 / Pharmacogenomics Reporter - Exact Sciences Discusses Benefits of Taking Cologuard through FDA/CMS Parallel Review Pilot
April 3, 2013 / Pharmacogenomics Reporter - Palmetto's Initial MDx Pricing Disappoints Industry; Raises Concerns about Business Impact
February 6, 2013 / Pharmacogenomics Reporter - Study Finds KRAS Testing in Metastatic CRC Saves Money, but Questions Value of EGFR Inhibitors
November 28, 2012 / Pharmacogenomics Reporter